← Back to headlines
Capricor Stock Falls as FDA Schedules Duchenne Therapy Review Meeting
Capricor's stock experienced a decline following the FDA's announcement of an AdCom meeting to review its Duchenne therapy.
26 Jun, 13:59 — 26 Jun, 13:59
Sources
Showing 1 of 1 sources
